BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMIBUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001. Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427 Tel.: 22618452/22661541, Tel/Fax: 22618327

Date: 07th September, 2022

To,
The Corporate Service Department,
BSE Limited
P.J. Towers, Dalal Street,
Mumbai- 400001.

Scrip Code: 524516

Sub: Submission of Annual Report under Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir / Madam,

Please find enclosed Notice of 35th Annual General Meeting and copy of Annual Report as per Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the year ended 31st March, 2022 for your records.

Kindly take note of the same and oblige.

For Bacil Pharma Limited

Prakash Shah Director

DIN: 01136800

Encl.: Annual Report for the year ended 31st March, 2022.

35th ANNUAL REPORT 2021-2022

BACIL PHARMA LIMITED

71, Laxmi Building, Sir P. M. Road, Fort, Mumbai – 400 001

Board of Directors

Prakash Shah – Director
Dr. Sneha Shah – Non-Executive Woman Director
Shirish Shetya – Independent Non-Executive Director
Lalit Jain – Independent Non-Executive Director
Manmohan Ghildyal – Manager
Jayesh Ramchandra Patil – Chief Financial Officer
Vaishali Sureshbhai Vaghasiya – Company Secretary

Registered Office

71, Laxmi Building, Sir P. M. Road, Fort, Mumbai – 400 001 www.bacilpharma.com E-mail: info@bacilpharma.com

E-mail: info@bacilpharma.com CIN: L24200MH1987PLC043427

Bankers

Union Bank of India Mumbai Samachar Marg, Mumbai – 400 023

Auditors

M/s. Laxmikant Kabra & Co. LLP (Formerly known as Laxmikant Kabra & Co.) Chartered Accountants Thane

Secretarial Auditor

Pooja Gandhi & Associates Practicing Company Secretary Mumbai

Registrar & Share Transfer Agents

Bigshare Services Pvt. Ltd. E-2/3, Ansa Industrial Estate, Sakivihar Road, Saki Naka, Andheri (East), Mumbai – 400 072

Phone: 28470652, 28470653, 28473747, 28473474

Fax: 28475207

www.bigshareonline.com

Special Notice to Shareholders holding shares in Physical Mode:

As per SEBI circular dated April 20, 2018 shareholders whose ledger folios not mapped with PAN and Bank details are requested to compulsorily furnish the details to the RTA/Company for registering the same with the respective folios.

For any queries on the subject matter and the rules. Please contact the Company's Registrars and Share transfer Agent at: BIGSHARE SERVICES PVT. LTD. E-2/3, Ansa Industrial Estate, Sakivihar Road, Saki Naka, Andheri (East), Mumbai - 400 072.

Telephone Number: 28470652, 28470653, 28473747, 28473474

email ID: info@bigshareonline.com

NOTICE

Notice is hereby given that the Thirty Fifth Annual General Meeting of the shareholders of Bacil Pharma Limited will be held on Thursday, 29th September, 2022, at 2.00 P.M at 71, Laxmi Building, 4th Floor, Sir P. M. Road, Fort, Mumbai – 400001 to transact the following business:

ORDINARY BUSINESS:

- To receive, consider, and, adopt the Audited Financial Statements of the Company as at 31st March, 2022 and Reports
 of the Directors' and Auditors' thereon.
- 2. To re-appoint M/s. Laxmikant Kabra & Co. LLP, Chartered Accountants as statutory auditors of the Company and to fix their remuneration:

"RESOLVED THAT pursuant to Section 139, 142 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s) or re-enactment thereof) and pursuant to the recommendations of the Audit Committee and the Board of Directors of the Company, M/s. Laxmikant Kabra & Co. LLP, Chartered Accountants, having registration No. 117183W be and are hereby re-appointed as the Statutory Auditors of the Company for term of five consecutive years, who shall hold office from the conclusion of this 35th Annual General Meeting till the conclusion of the 40th Annual General Meeting to be held in the year 2027 on such remuneration as may be decided by the Board of Directors in consultation with the Statutory Auditors of the Company."

Special Business:

3. To appoint Mrs. Suman Shah (DIN: 01764668) as Non-Executive Non-Independent Director of the Company.

To consider and if thought fit, to pass the following Resolution as an Ordinary Resolution:

"RESOLVED that pursuant to the provisions of Section 152, 160 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), Mrs. Suman Shah (DIN: 01764668), in respect of whom the Company has received a notice in writing from a Member under Section 160 of the Act, proposing her candidature as a Director, be and is hereby appointed as Non-Executive Non-Independent Director of the Company from the date of this 35th Annual General Meeting, liable to retire by rotation."

RESOLVED FURTHER that the Board of Directors of the Company, be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, desirable or expedient to give effect to this Resolution."

Place: Mumbai For & on behalf of the Board of Directors
Date: 01.09.2022 Bacil Pharma Limited

REGISTERED OFFICE

71, Laxmi Building, 4th Floor, Sir P M Road, Fort, Mumbai-400001 Sd-Prakash Shah Director DIN: 01136800

NOTES

- 1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND SUCH A PROXY NEED NOT BE A MEMBER OF THE COMPANY. The instrument appointing proxy should, however be deposited at the registered office of the Company not less than forty-eight hours before the commencement of the meeting. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.
- 2. Corporate Members intending to send their authorized representatives to attend the Meeting pursuant to Section113 of the Companies Act, 2013 are requested to send to the Company a certified copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the Meeting.
- 3. The Register of Members and Share Transfer Books of the Company will remain closed from Friday, 23rd September, 2022 to Thursday, 29th September, 2022 (both days inclusive).
- 4. Members are requested to expeditiously intimate any change in their address registered with the Company. Members holding shares in physical form can submit their PAN details to the Company / Registrars and Transfer Agents, M/s. BIGSHARE SERVICES PVT. LTD.
- 5. Members are requested to bring their attendance slip along with copy of the Annual Report at the time of Annual General Meeting.
- 6. The Notice of AGM along with the Annual Report 2021-22 is being sent by electronic mode to those members whose email addresses are registered with the Company / Depositories.
- 7. Shareholders desiring any information as regards the proposed resolutions are requested to write to the Company at least seven working days in advance so as to enable the management to keep the information ready at the meeting.
- 8. In the terms of Section 72 of the Companies Act, 2013, nomination facility is available to the individual shareholder. The shareholders who are desirous of availing this facility may kindly write to the Registrars & Transfer Agents in Form SH-13 prescribed by the Government which can be obtained from the Company's R&T Agents.
- 9. A Statement pursuant to Section 102(1) of the Companies Act, 2013, relating to the special business to be transacted at the Meeting is annexed hereto.
- 10. The remote e-voting period begins on Monday, September 26, 2022 (9.00 A.M. Indian Standard Time) and ends on Wednesday, September 28, 2022 (5.00 P.M. Indian Standard Time). The remote e-voting module shall be disabled by NSDL for voting thereafter.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

areholders holding securities in demat mode is given below: Login Method		
(i) Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under "IDeAS' section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDLand you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period. (ii) If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp (iii) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDLand you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period. (iv) Shareholders/Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App is available on		

Individual Shareholders holding securities in demat mode with CDSL	Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest arehttps://web.cdslindia.com/myeasi/home/loginor www.cdslindia.com and click on New System Myeasi.	
	 After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of e- Voting service provider i.e. NSDL. Click on NSDL to cast your vote. 	
	3. If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration on	
	4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. NSDL where the e-Voting is in progress.	
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period	

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.inor call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738 or 022-23058542-43

B) Login Method for e-Voting shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

- 1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
- 2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
- 3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen. Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
- 4. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12******************* then your user ID is 12************************************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

- 5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
 - c) How to retrieve your 'initial password'?
 - If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.

- 6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
 - a) Click on "Forgot User Details/Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
- 7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
- 8. Now, you will have to click on "Login" button.
- 9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically on NSDL e-Voting system. How to cast your vote electronically on NSDL e-Voting system?

- I. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle.
- II. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period Now you are ready for e-Voting as the Voting page opens.
- III. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
- IV. Upon confirmation, the message "Vote cast successfully" will be displayed.
- V. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
- VI. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

- Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to sgevoting@gmail.com with a copy marked to evoting@nsdl.co.in
- 2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
- 3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request at evoting@nsdl.co.in

Process for those shareholders whose email ids are not registered with the depositories/ company for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to bacilpha@yahoo.com.

- 2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to sanmitracommercial@ymail.com. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting for Individual shareholders holding securities in demat mode.
- 3. Alternatively shareholder/members may send a request to evoting@nsdl.co.infor procuring user id and password for e-voting by providing above mentioned documents.
- 4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.
- 5. The voting rights of members shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date of September 22, 2022.
- 6. Any person, who acquires shares of the Company and become member of the Company after dispatch of the notice and holding shares as of the cut-off date i.e. September 22, 2022, may obtain the login ID and password by sending a request at evoting@nsdl.co.in or RTA.
- 7. A member may participate in the AGM even after exercising his right to vote through remote e-voting but shall not be allowed to vote again at the AGM.
- 8. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote evoting as well as voting at the AGM through ballot paper.
- 9. Mr. Suhas Ganpule, Practicing Company Secretary, (COP No. 5722) has been appointed for as the Scrutinizer for providing facility to the members of the Company to scrutinize the voting and remote evoting process in a fair and transparent manner.
- 10. The Chairman shall, at the AGM, at the end of discussion on the resolutions on which voting is to be held, allow voting with the assistance of scrutinizer, by use of "remote e-voting" or "Ballot Paper" " for all those members who are present at the AGM but have not cast their votes by availing the remote e-voting facility.
- 11. The Scrutinizer shall after the conclusion of voting at the general meeting, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than three days of the conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favor or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
- 12. The Results declared along with the report of the Scrutinizer shall be placed on the website of NSDL immediately after the declaration of result by the Chairman or a person authorized by him in writing. The results shall also be immediately forwarded to the BSE Limited, Mumbai.

Place: Mumbai Date: 01.09.2022 For & on behalf of the Board of Directors

Bacil Pharma Limited

REGISTERED OFFICE 71, Laxmi Building, 4th Floor, Sir P. M. Road, Fort, Mumbai – 400 001 Sd_ Prakash Shah Director DIN: 01136800

EXPLANATORY STATEMENT IN RESPECT OF THE ITEMS OF THE NOTICE PURSUANT TOSECTION 102(1) OF THE COMPANIES ACT, 2013

Item No. 2: Reappointment of M/s. Laxmikant Kabra & Co. LLP, Chartered Accountants as Statutory Auditors of the Company.

This Explanatory Statement is provided though strictly not required as per Section 102 of the Act.

LAXMIKANT KABRA & CO LLP, Chartered Accountants, Mumbai (ICAI Firm Registration No.: 117183W/ W100736) were appointed as the Statutory Auditors of the Company by the Members at the 30th Annual General Meeting (AGM) held on September 29, 2017 to hold office from the conclusion of the 30th AGM till the conclusion of the 35th AGM of the Company to be held in the calendar year 2022. Accordingly, the present term of LAXMIKANT KABRA & CO LLP expires on conclusion of the ensuing 35th AGM. LAXMIKANT KABRA & CO LLP are eligible for re-appointment for a second term of five years in terms of the provisions of Section 139 of the Act read with the Companies (Audit and Auditors) Rules, 2014. The Company has received eligibility letter from LAXMIKANT KABRA & CO LLP confirming that their appointment will be in accordance with the provisions of Section 139 read with Section 141 of the Act. Considering their performance for the last 5 years, the Audit Committee of Directors has recommended the reappointment of LAXMIKANT KABRA & CO LLP to the Board of Directors of the Company, which the Board has accepted and approved, subject to the approval of the Members.

The remuneration proposed to be paid during their term would be mutually agreed between the Board of Directors of the Company and the Auditors and shall commensurate with the services to be rendered by them during the said tenure. The Board of Directors in consultation with the Audit Committee may alter and vary the terms and conditions of appointment, including remuneration, in such manner and to such extent as may be mutually agreed with the Statutory Auditors.

The Board recommends the resolution set out at Item No. 3 of the Notice for approval by the Members by way of an Ordinary Resolution.

None of the Directors or Key Managerial Personnel of the Company or their relatives are interested or concerned, financially or otherwise, in the resolution.

Item No. 3: Appointment of Mrs. Suman Shah (DIN: 01764668) as Non-Executive Non-Independent Director of the Company.

The Company has received a notice in writing from a shareholder in accordance with section 160 of the Companies Act, 2013, proposing her candidature for the Director. The Board of Directors is of view that presence of Mrs. Suman Shah on the Board is desirable and would be beneficial to the Company and accordingly recommends Ordinary Resolution set forth in item No. 3 of the notice for approval of the members.

Except Mr. Prakash Shah and Dr. Sneha Shah, no other Director or Key Managerial Personnel of the Company or their relatives are concerned or interested in the proposed resolution.

Place: Mumbai Date: 01.09.2022 For & on behalf of the Board of Directors

Bacil Pharma Limited

REGISTERED OFFICE 71, Laxmi Building, 4th Floor, Sir P. M. Road, Fort, Mumbai – 400 001 Sd_ Prakash Shah Director DIN: 01136800

Detail of Directors seeking appointment at the Annual General Meeting.

Name of Director	Mrs. Suman Shah		
DIN	01764668		
Date of Birth	19/04/1960		
Date of original appointment	30/09/2022		
Relationship with Directors	Related to Mr. Prakash Shah		
Expertise in specific functional	General Business		
Area			
Qualification(s)	M. A. Political Science		
Directorship held in other Listed Companies	1. Sanmitra Commercial Ltd.		
	2. New Markets Advisory Ltd.		
Chairmanship/Membership of committees	N.A.		
of other public companies			
Number of Shares held in the Company as on 31 March, 2022	1400		

DIRECTORS' REPORT

To, The Members

Bacil Pharma Limited

Your Directors have pleasure in presenting Thirty Third Annual Report together with the Audited Accounts of the Company for the year ended 31st March 2022.

Financial Highlights: (Amt in Lakhs)

PARTICULARS	2021-2022	2020-2021
Profit/ (Loss) for the year before providing Depreciation	(385.63)	(23.48)
Less: Depreciation	0.37	0.49
Profit/(Loss) after providing Depreciation and Before Tax	(386.00)	(23.97)
Current Tax		
Deferred Tax	0.02	0.04
Profit/(Loss) from ordinary activities after Tax	(385.98)	(23.92)
Comprehensive Income	(0.26)	33.21
Tax relating to such income	0.07	(8.82)
Reclassification of Loss on Asset held for sale	369.48	0.00
Profit/(Loss) for the Period	(16.69)	0.47

Dividend:

In view of accumulated losses, your Directors did not recommend any dividend for its equity shareholders.

State of Company's Affairs and Future Outlook:

During the period under consideration, the Company, in spite of all the efforts could not commence any business activities.

The company during the year has not carried out any major business activity and the management is also considering for diversification of business activities. However in order to generate revenue to afford part of fixed expenses of the company, the management has decided to utilize the surplus funds and deployed the same as temporary loans and advances.

Disposal of Assets:

As informed earlier the company had entered into an agreement for Slump Sale of Drug/ Chemical intermediate plant at MIDC Industrial Area, Lote Parshuram, Dist. Ratnagiri in FY 2017-18 on as is where is basis. Registration was completed for single unit having Reckoner Value of Rs. 28,21,477. Since the Drug/ Chemical intermediate plant was sold under slump sale, the registration of single unit was not been treated as sale and capital gain/ loss for the same has not been charged to profit and loss in F. Y. 2020-21. The Registration of the main unit was delayed due to obtaining permission from the competent authority for payment of stamp duty and the same was completed in the month of February 2021 and sale of the entire unit has been accounted for in this financial year.

Company has incurred long term capital loss on sale of drug/ chemical intermediate plant at Lote Parshuram MIDC, Ratnagiri. The diminution in the value of the asset was shown as other comprehensive income during in F.Y. 2017-18 as the asset was recognised as "held for sale". However, on account of various registration and compliance issues the sale could not be completed. As the process of registration of sale of the above said assets has been completed during this F.Y. 2021-22, the loss on account of sale disclosed under other comprehensive income in F.Y. 2017-18 has now been recognized and debited to Profit & Loss Account.

Deposits:

Your Company has not accepted any deposits within the meaning of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

Transfers to Reserves:

In view of accumulated losses the Company was not required to transfer any amount to the Reserves.

Details of Subsidiary/ Joint Venture/ Associates Company:

Pursuant to provisions of Companies Act, 2013 Company does not have any Subsidiary/ Joint Venture and Associate Companies.

Impact of Covid-19 pandemic:

The outbreak of COVID-19 was declared as a pandemic by the World Health Organization, which has infected millions number of people globally. Covid-19 is seen having an unprecedented impact on people and economies worldwide.

The spread of COVID-19 pandemic affected activities of businesses across the globe. In many countries, including India, there has been severe disruption to regular business operations due to lock-downs, disruptions in transportation, travel bans, quarantines, social distancing and such other emergency measures. In assessing the recoverability of receivables, inventories, loans and other financial assets, the Company has considered internal and external information up to the date of approval of the financial statements. Considering the uncertainties involved in estimating the impact of this pandemic, the future impact of this pandemic may be different from those estimated as on the date of approval of these financial statements.

We are closely monitoring the situation and will take all necessary actions as may be required in the interest of all stakeholders. The Company is following Government Directives regarding health and safety of all employees and has already adopted the practice of work from home for its employees in order to minimize the risk and contain the spread of COVID-19. In the operations, focus is being maintained on social distancing and hygienic practices, for the safety of the people.

Share Capital:

The paid up equity capital as on March 31, 2022 was Rs. 5,89,00,000/- The Company has not bought back any securities or issued any Sweat Equity shares or bonus shares or provided any stock option scheme to employees during the year under review.

Extract of Annual Return

Pursuant to the provisions of Section 134(3)(a) of the Companies Act,2013, the Annual Return for the Financial Year ended March 31, 2022 is available on the website of the Company.

Number of Board Meetings:

During the Financial Year 2021-22, Five Meetings of the Board of Directors of the company were held. The date of the meetings of the board held is as under-

Sr. No.	Date of Meeting	Total strength of the Board	No. of Directors Present
01	30 th June, 2021	4	4
02	14 th August, 2021	4	4
03	31st August, 2021	4	3
04	12 th November, 2021	4	4
05	14 th February, 2022	4	4

Independent Directors' Meeting:

During the year under review, Independent Directors met on 14th February 2022, inter-alia, to discuss:

- Evaluation of the performance of Non-Independent Directors and the Board as whole.
- Evaluation of the performance of the Chairman of the Company, taking into account the views of the Executive and Non-Executive Directors.
- Evaluation of the quality, quantity content and timeless of flow of information between the management and the Board.

Particulars of Loan, Guarantees and Investments under Section 186:

Complete details of Loan, Guarantee/Security/ Investments covered under section 186 of The Companies Act, 2013 as attached in the financial statement and notes there under.

Particulars of Contracts or Arrangements with Related Parties:

During the year, the Company had not entered into any contract / arrangement / transaction with related parties which could be considered material in accordance with the policy of the Company on materiality of related party transactions, The Policy on materiality of related party transactions and dealing with related party transactions as approved by the Board.

Conservation of Energy, Technology, Absorption, Foreign Exchange Earnings and Outgo:

As required under Rule 8 (3) of the Companies (Accounts) Rules, 2014, the particulars relating to the conservation of energy, technology absorption and the foreign exchange earnings and out go are NIL.

Internal Control System:

The Company has proper and adequate internal control systems commensurate with the nature of its business, and size and complexity of its operations. Internal control systems comprising of policies and procedures are designed to ensure reliability of financial reporting, timely feedback on achievement of operational and strategic goals, compliance with policies, procedure, applicable laws and regulations, and all assets and resources are acquired economically, used efficiently and adequately protected.

Details of Directors and Key Managerial Personnel:

Sr.	Name and Address	Designation	Date of Appointment	DIN
1.	Mr. Manmohan Singh Ghildyal	Manager	10/06/2002	AFVPG9931N
2.	Mr. Prakash Shah	Director	09/08/1990	01136800
3.	Dr. Sneha Shah	Director	31/03/2015	07303755
4.	Mr. Shirish Suryakant Shetye	Independent Director	25/03/2003	00148086
5.	Mr. Lalit Jain	Independent Director	24/02/2012	07619530
6.	Mr. Jayesh Ramchandra Patil	CFO	31/03/2015	ATPPP3597F
7.	Ms. Vaishali Vaghasiya	Company Secretary	19/10/2020	ALCPV0516D

In accordance with the provisions of the Act and the Articles of Association of the Company Dr. Sneha Shah (DIN: 07144208), has not offered herself for reappointment.

The Company has received Declarations from all the Independent Directors of the Company confirming that they meet the criteria of independence as prescribed both under the Act and under Regulations of the SEBI (LODR), Regulations, 2015.

Board Evaluation:

Formal Annual evaluation has been made by the Board of its own Performance and that of its Committees & Individual Directors during the meeting of Board of Directors and by common discussion with concerned persons.

Particulars relating to Remuneration of Employees:

None of the Directors receive any remuneration nor receive any sitting fees.

During the Financial Year the percentage increase in remuneration of Directors and Key Managerial Personnel is as follows:

Name of the Director	Designation	Percentage Increase/decrease in the Remuneration
Mr. Jayesh Ramchandra Patil	CFO	NIL
Mr. Man Mohan Ghildyal	Manager	NIL
Ms. Vaishali Vaghasiya	Company Secretaryand Compliance Officer	NIL

- 3. As on 31st March 2022, there were a total of 3 employees on the pay roll of the Company.
- 4. It is affirmed that the remuneration is as per the remuneration policy of the company.
- 5. The Company does not have any Holding or Subsidiary Company and none of the Directors of the Company are the Managing Director or Whole Time Director in the Associate Company.

Audit Committee:

The Audit Committee comprises of Independent Non-Executive Directors namely Mr. Shirish S. Shetye as Chairman and Mr. Lalit Jain as member and Non-Executive Director Mrs. Sneha Shah as member.

The Members of Audit Committee meet four (4) Times during the year i.e. 30.06.2021, 14.08.2021, 12.11.2021 & 14.02.2022.

Recommendations, if any, made by the Audit Committee were accepted by the Board.

Nomination & Remuneration Committee & Policy:

In compliance with section 178 of the Act the Board has constituted "Nomination and Remuneration Committee" which comprises Independent Non-executive Directors namely Mr. Shirish S. Shetye as Chairman and Mr. Lalit Jain as Member and Non-Executive Director Mrs. Sneha Shah as member. During the year 2021-2022 the Nomination & Remuneration Committee had one meeting on 14.08.2021

The Board has framed a policy for selection and appointment of Directors, Senior Management and their remuneration.

Stakeholders Relationship Committee:

This Committee comprises of Independent Non-Executive Directors Mr. Shirish S. Shetye as Chairman and Mr. Lalit Jain as Member and Non-Executive Director Mrs. Sneha Shah as Member. During the year ended 31st March, 2021 Stake holder Relationship Committee had four meetings. 30.06.2021, 14.08.2021, 12.11.2021 & 14.02.2022

The Company during the year had not received any complaint and there were no pending complaint as on March 31, 2022.

Transfer of amounts of unpaid dividend to investor education and protection fund:

There are no amounts due and outstanding to be credited to investor Education and Protection Fund as 31st March, 2022.

Disclosure on Establishment of a Vigil Mechanism:

The Company has Vigil Mechanism/Whistle Blower Policy to deal with instance of fraud and mismanagement, if any. No personnel had been denied access to the Audit Committee to lodge their grievances.

Corporate Social Responsibility Initiatives:

As the Company does not fall under the Class of Companies as prescribed under Section 135 of Companies Act, 2013 and Rules made thereunder, therefore the provisions related to Corporate Social Responsibility is not applicable to the Company.

Code for prevention of insider trading:

The Company has adopted a Code of Conduct for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and designated employees of the Company. The Code requires preclearance for dealing in the Company's shares and prohibits the purchase or sale of Company shares by the Directors and the designated employees while in possession of unpublished price sensitive information in relation to the Company and during the period when the Trading Window is closed. The Board is responsible for implementation of the Code. All Board Directors and the designated employees have confirmed compliance with the Code.

Significant and material orders passed by the regulators or courts:

There are no significant and material orders passed by the Regulators / Courts which would impact the going concern status of the Company and its future operations.

Risk management policy:

The Board has adopted risk Management policy for ensuring the orderly and efficient conduct of its business, including adherence to company's policy, safeguarding of its assets, Prevention detection fraud and error etc.

Disclosures under Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013:

There were no complaints reported under the prevention of Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013.

Fraud Reporting in Auditors Report as per Second proviso of Section 143 (12) of the Companies Act, 2013:

No Fraud reported / observed in Audit Report during the financial year 2021 -22.

AUDITORS:

Statutory Auditors:

The auditors M/s. Laxmikant Kabra & Co. LLP, Chartered Accountants, having registration No. 117183W are re-appointed as the Statutory Auditors of the Company for term of five consecutive years in accordance with the provisions of the Companies Act, 2013, who shall hold office from the conclusion of this 35th Annual General Meeting till the conclusion of the 40th Annual General Meeting to be held in the year 2027 on such remuneration as may be decided by the Board of Directors in consultation with the Statutory Auditors of the Company. Appointment is in terms of provisions of section 139 (1) of M/s Laxmikant Kabra & Co., Chartered Accountants, as statutory auditors of the Company for the term of 5Years.

Auditors Report:

The Report of M/s Laxmikant Kabra & Co LLP (Formerly known as Laxmikant Kabra & Co.) for the financial year 2021-2022 do not contain any qualifications, observations or comments on the Financial transactions or matters which have any adverse effect on the functioning of the Company, however following observation made by the Auditor.

Key Audit Matter	How the matter was addressed in our Audit
The company has given unsecured loans and advances to	We have recognized the same on the fair value and
various parties which is not the main object / core business	interest income is recognized on accrual basis.
activity of the company.	However, if the interest is not recoverable then
	management does not recognise the same.

Secretarial Audit Report:

A Secretarial Audit was conducted during the year by the Secretarial Auditor, M/s Pooja Gandhi &Co., Practicing Company Secretaries, Mumbai, in accordance with Provisions of Section 204 of the Act. The Secretarial Auditors Report is attached as Annexure II and forms part of this Report.

The Secretarial Auditors have in their report observed as follows:

Non-Compliance with regulation 31 regarding the entire promoter shareholding to be in dematerialized form and less than 50% public holding is in dematerialized form.

Cost Auditors:

Requirements for Appointment of Cost Auditors are not applicable to the company.

Stock Exchange:

The Company's equity shares are listed at BSE Limited vide scrip code 524516 and the Annual Listing Fees for the year 2021-2022 has been paid.

Directors Responsibility Statement:

In accordance with the provisions of Section 134(5) of the Companies Act 2013, your directors confirm that:

- a) In the preparation of the annual accounts for the financial year ended 31st March, 2022, the applicable Ind-AS had been followed along with proper explanation relating to material departures;
- b) The directors had selected such accounting policies and applied them and made judgments and estimates that are reaprudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2022.
- c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) The directors had prepared the annual accounts on a going concern basis;
- e) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.
- f) The proper internal financial controls are in place and that such internal financial controls are adequate and are operating effectively.
- g) The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Acknowledgment:

The Directors express their sincere appreciation to the valued shareholders, bankers, professionals, clients and devoted employees for their support.

For and on behalf of the Board of Directors

Place: Mumbai Sd- SdPlace: 01.09.2022 Sd- Mr. Prakash Shah Mr. Shirish Shetye
Date: 01.09.2022 Director Director

DIN: 01136800 DIN: 00148086

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules,2014.)

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transactionunder third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

SL. No.	Particulars	Details
a)	Name (s) of the related party & nature of relationship	NA
b)	Nature of contracts/arrangements/transaction	NA
c)	Duration of the contracts/arrangements/transaction	NA
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	NA
e)	Justification for entering into such contracts or arrangements or transactions'	NA
f)	Date of approval by the Board	NA
g)	Amount paid as advances, if any	NA
h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	NA

2. Details of contracts or arrangements or transactions at Arm's Length Basis:

Particular		Salient Term of the Contract	Amount of Transaction	
Name of Related party	Nature of Relation	Name of Transaction		
Prakash Shah	Director	Loans and Advances (Loan Taken)	On demand	3,31,302

For and on behalf of the Board of Directors

Place: Mumbai Sd- SdMr. Prakash Shah Mr. Shirish Shetye
Date: 01.09.2022 Director Director

DIN: 01136800 DIN: 00148086

FORM NO. MR 3 SECRETARIAL AUDIT REPORT

[Pursuant to Section 204 (1) of the Companies Act 2013 and Rule No 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

For the Financial Year Ended March 31, 2022

To,

The Members,

Bacil Pharma Limited

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Bacil Pharma Limited (hereinafter called the Company).

Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion the Company has, during the audit period covering the financial year ended on March 31, 2022 has complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2022 according to the provisions of:

- I) The Companies Act, 2013 (the Act) and the rules made there under;
- II) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under,
- III) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- IV) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (Not Applicable during the year under review)
- V) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011:
 - b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c) The Securities and Exchange Board of India (Mutual Funds) Regulations, 1996; Not Applicable
 - d) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 - The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
 Not Applicable
 - f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;

We further state that there were no events/ actions in pursuance of the following Regulations and Guidelines prescribed under the Securities and Exchange Board of India act, 1992 (SEBI Act): -

- The Securities and Exchange Board of India (Employee Stock Option Schemeand Employee Stock Purchase Scheme)
 Guidelines, 1999:
- The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
- 3) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009;
- 4) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018.
- 5) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014.
- 6) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013.

All other relevant laws applicable to the Company, a list of which has been provided by the management. The examination and reporting of these laws and rules are limited to whether there are adequate systems and processes in place to monitor and ensure compliance with those laws.

We further report that having regards to the compliance system prevailing in the Company and on examination of the relevant documents and records in pursuance thereof on test check basis, the Company has complied with the following laws applicable specifically to the Company:

- Micro, Small and Medium Enterprises Development Act, 2006
- The Central Goods and Services Tax Act, 2017
- State Goods and Service Tax Act, 2017
- Integrated Goods and Services Tax Act, 2017

The Company has generally complied with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Listing Agreements entered into by the Company with BSE Limited.

We have also examined compliance with the applicable clauses of the following:

(i) Secretarial Standards with regard to meeting of the Board of Directors (SS-1) and General Meeting (SS-2) issued by the Institute of Company Secretaries of India.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. to the extent applicable except the following:

Non-Compliance with regulation 31 regarding the entire promoter shareholding to be in dematerialized form and less than 50% public holding is in dematerialized form.

We further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All the decisions were carried out unanimously by the members of the Board and the same were duly recorded in the minutes of the meeting of the Board of Directors.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period, there are no instances of:

- i. Public / Right/ Preferential issue of shares / debentures / sweat equity.
- ii. Redemption/Buy-Back of securities.
- iii. Major decisions taken by the Members in pursuance to Section 180 of the

Companies Act, 2013.

- iv. Merger / Amalgamation / Reconstruction etc.
- v. Foreign technical collaborations.

For Pooja Gandhi & Co. Practicing Company Secretaries

Sd-CS Pooja Gandhi Proprietor

ACS: 22838, COP:20135 UDIN: A022838D000534811

Date: 27.06.2022 Place: Mumbai

Peer Review Cer No.: 1367/2021

Annexure 'A'

To The Members, Bacil Pharma Limited

Our report of even date is to be read along with this letter:

- 1. Maintenance of secretarial record is the responsibility of the Management of the Company. Our responsibility is to express an opinion on these secretarial records based on my audit.
- 2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial record. The verification was done on test basis to ensure that the correct facts are reflected in secretarial records. We believe that the practices and processes, we followed provide a reasonable basis for our opinion.
- 3. We have not verified the correctness and appropriateness of financial records and books of accounts of the company.
- 4. Wherever required, we have obtained Management representation about the compliance of laws, rules, regulations, norms and standards and happening of events.
- 5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, norms and standards is the responsibility of Management. Our examination was limited to the verification of procedure on test basis.
- 6. The secretarial audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

For Pooja Gandhi & Co. Practicing Company Secretaries

Sd-

CS Pooja Gandhi Proprietor

ACS: 22838, COP: 20135 UDIN: A022838D000534811

Date: 27.06.2022 Place: Mumbai

Peer Review Cer No.:1367/2021

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of BACIL PHARMA LIMITED Report on the Audit of Financial Results Opinion

We have audited the annual financial results of BACIL PHARMA LIMITED(hereinafter referred to as the 'Company") for the year ended March 31, 2022 and the Balance Sheet and the Statement of Cash Flows as at and for the year ended on that date, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial results:

- are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the Listing Regulations in this regard;
 and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2022 and the balance sheet and the statement of cash flows as at and for the year ended on that date.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be key audit matters to be communicated in our report.

Key Audit Matter	How the matter was addressed in our Audit
The company has given unsecured loans and advances to	We have recognized the same on the fair value and interest
various parties which is not the main object / core business	income is recognized on accrual basis. However, if the interest is
activity of the company.	not recoverable then management does not recognise the same.

Emphasis of Matter

- Recoverability of the balances of loans and advances given to various parties are yet to be determined by the management. These
 loans and advances are subject to confirmation by management.
- 2. Company has incurred long term capital loss on sale of drug/ chemical intermediate plant at Lote Parshuram MIDC, Ratnagiri. The diminution in the value of the asset was shown as other comprehensive income during in F.Y. 2017-18 as the asset was recognised as "held for sale". However, on account of various registration and compliance issues the sale could not be completed. As the process of registration of sale of the above said assets has been completed during this F.Y. 2021-22, the loss on account of sale disclosed under other comprehensive income in F.Y. 2017-18 has now been recognized and debited to Profit & Loss Account.

Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report but does not include the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and we do not express anyform of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibilities for the Financial Results

These financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the balance sheet and the statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of

adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial results by the Directors of the Company, as aforesaid.

In preparing the financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- d. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are Inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the financial results including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

- As required by the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms
 of Section 143(11) of the Act, we give in the "Annexure 1" a statement on the matters specified in paragraphs 3 and 4 of the
 Order.
- 2. As required by Section 143(3) of the Act, we report that:
 - a) Apart from matters stated in emphasis of matter paragraph, we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
 - b) In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appears from our examination of those books.

ANNUAL REPORT 2021-22

Place: Thane

Date: 30th May 2022

BACIL PHARMA LIMITED

c) The Balance Sheet, the Statement of Profit and Loss including other comprehensive income, the statement of change in equity and the Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account.

d) In our opinion, the aforesaid financial statements comply with Ind AS specified under Section 133 of the Act.

e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2022, from being appointed as a director in terms of Section 164(2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure 2" to this report.

g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:

a) The Company has no pending litigations as of March 31, 2022, on its financial position in its standalone financial statements

b) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

 There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; The management has represented that, to the best of its knowledge and belief, no funds have been received by the Company from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

Based on such audit procedures that were considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.

In our opinion and to the best of our information and according to the explanation given to us, the company has not paid any remuneration to its directors during the year. Hence the provisions of Section 197 of the Act are not applicable.

For Laxmikant Kabra & Co LLP

Chartered Accountants FRN.: 117183W/ W100736

Sd-

CA Laxmikant Kabra Partner

Membership No.: 101839 UDIN: 22101839AMEBNZ9087

ANNEXURE 'A' TO THE INDEPENDENT AUDITORS' REPORT:

The Annexure referred to in Independent Auditor's Report to the members of the Company on the financial statements for the year ended 31stMarch 2022, we report that:

i.

- a. The Company has maintained proper records showing full particulars, including quantitative details and situation of its fixed assets.
- b. The Company has a regular programme of physical verification of its property plant and equipment by which fixed assets are verified in a phased manner over a period of three years. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. In accordance with this programme, certain property plant and equipment were verified during the year and no material discrepancies were noticed on such verification.
- c. According to the information and explanations given to us and on the basis of our examination of the records of the company, company does not have any immovable property.
- d. The Company has not revalued its Property, Plant and Equipment (including Right of use assets) during the year ended 31st March 2022.
- e. There are no proceedings initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- ii. As per the information and explanations given to us, the company does not have any inventory. Accordingly, clause 3(ii) of the order is not applicable to the company.
- iii. During the year the company has not made any investments in or provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties or to promoters or related parties. Accordingly, clause 3(iii) of the order is not applicable to the company.
- iv. The company has not granted any loans, or made any investments, guarantees, and security, to which the provisions of sections 185 and 186 of the Companies Act 2013 apply.
- v. The Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of Sections 73 to 76 of the Companies Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
- vi. To the best of our knowledge and explanation given to us, the provisions of maintenance of cost records under sub section (1) of Section 148 of the Act are not applicable to Company for the financial year 2020-21. Accordingly, the requirement to report on clause 3(vi) of the Order is not applicable to the Company.

vii.

- a. Undisputed statutory dues including provident fund, employees' state insurance, income-tax, Goods and Service Tax, Custom Duty and other material statutory dues have generally been regularly deposited with the appropriate authorities though there has been a slight delay in a few cases.
- According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, Goods and Service tax, Custom Duty and other material statutory dues were outstanding for the year end, for a period of more than six months from the date they became payable.
- b. According to the records of the Company, there are no dues outstanding of income-tax, sales- tax, service tax, duty of custom, duty of excise, value added tax and cess on account of any dispute for the year ended March 31, 2021.
- viii. The Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.

ix.

- a. Based on our audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to information and explanations given by the management, we are of the opinion that the Company has not defaulted in repayment of dues to a financial institution, bank or debenture holders or government.
- b. The Company has not been declared as a willful defaulter by any bank or financial institution or government or any government authority during the year.

BACIL PHARMA LIMITED

- c. During the year the company has not availed of or has been disbursed any term loans
- d. On an overall examination of the financial statements of the Company, no funds raised on short-term basis have been used for long-term purposes during the year by the Company.
- e. The company does not have any Subsidiary, Associates or Joint Ventures.
- f. The company does not have any Subsidiary, Associates or Joint Ventures.

x.

- a. The Company has not raised any money during the year by way of initial public offer/further public offer (including debt instruments) hence, the requirement to report on clause 3(x)(a) of the Order is not applicable to the Company.
- b. During the year the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause (x)(b) of the Order is not applicable to the Company.

xi.

- a. No fraud by the Company or no fraud on the Company has been noticed or reported during the year
- b. There is no instance, during the year that necessitates reporting in the form ADT-4
- c. There are no instances of whistle-blower complaints received by the company during the year.
- xii. The Company is not a Nidhi Company as per the provisions of the Companies Act, 2013. Therefore, the requirement to report on clauses 3(xii)(a), (b) and (c) of the Order is not applicable to the Company.
- xiii. In our opinion, transactions with the related parties are in compliance with Sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.

xiv.

- a. The Company has an internal audit system commensurate with the size and nature of its business.
- b. The internal audit reports of the Company issued till the date of the audit report, for the period under audit have been considered by us.
- xv. The Company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence requirement to report on clause 3(xv) of the Order is not applicable to the Company.

xvi.

- a. The provisions of Section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause (xvi) (a) of the Order is not applicable to the Company
- b. The Company has not conducted any Non-Banking Financial or Housing Finance activities without obtaining a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934.
- c. The Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi) of the Order is not applicable to the Company
- d. There is no Core Investment Company as a part of the Group, hence, the requirement to report on clause 3(xvi) of the Order is not applicable to the Company.
- xvii. Since there were no operations during the year, the company has incurred loss on account of fixed cost. The profit and loss of other comprehensive income which relates to investment activities have not been considered for purpose of the said clause as the same has not been realised during the year.
- xviii. There has been no resignation of the statutory auditors during the year and accordingly requirement to report on Clause 3(xviii) of the Order is not applicable to the Company

Place: Thane

Date: 30th May 2022

- xix. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, we believe that there does not exists material uncertainty as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. Even though there are no operations or business in the company, management is of the opinion that company will start its operations. Also, Current assets of the company are more than current liabilities. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx. According to the information and explanation given to us provisions of section 135 of the Companies Act 2013 are not applicable to the company. Accordingly, the requirement to report on clause 3(xx) of the Order is not applicable to the Company.
- xxi. The company does not have any subsidiaries or associates or joint ventures, the accounts of which are to be consolidated and as such there are no consolidated financial statements.

For Laxmikant Kabra & Co LLP Chartered Accountants FRN:: 117183W/W100736

Sd-CA Laxmikant Kabra Partner

Membership No.: 101839 UDIN: 22101839AMEBNZ9087

ANNEXURE B TO INDEPENDENT AUDITOR'S REPORT

Referred to in paragraph 10(f) of the Independent Auditors' Report of even date to the members BACIL PHARMA LIMITED on the financial statements for the year ended March 31, 2022

Report on the internal financial controls under clause(i)of sub-section 3 of section 143 of the Act

We have audited the internal financial controls over financial reporting BACIL PHARMA LIMITED ('the Company') as of March 31, 2022, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's responsibility for internal financial controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the 'Guidance Note') and the Standards on Auditing deemed to be prescribed under section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of internal financial controls over financial reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

A company's internal financial control over financial reporting includes those policies and procedures that:

- Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company.
- Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company.
- Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent limitations of internal financial controls over financial reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Laxmikant Kabra & Co LLP

Chartered Accountants FRN::117183W/ W100736

Sd-

CA Laxmikant Kabra Partner

Partner Place: Thane
Membership No.: 101839 Date: 30th May 2022

UDIN: 22101839AMEBNZ9087

Balance Sheet as at 31st March, 2022

(Amount in ₹)

Particulars	Note No.	As at 31.03.2022	As at 31.03.2021
I. ASSETS			
1 Non-Current Assets			
Property, Plant and Equipments	3	1,09,209	1,46,384
Assets Classified as held for sale			
Property Plant and Equipments	3	0	2,50,00,000
Financial assets			
(a) Investments	4	4,97,235	23,56,230
(b) Loans	5	60,08,633	92,83,307
Deferred tax assets (net)	6	10,84,340	10,75,462
2 Current assets			
Financial assets			
(a) Investments	7	26,23,111	13,88,307
(b) Trade Receivable		-	-
(c) Cash and cash equivalents	8	22,97,366	9,90,361
Other current assets	9	95,799	6,43,044
Total		1,27,15,693	4,08,83,094
II. EQUITY AND LIABILITY			
1 Equity			
Equity Share Capital	10	6,52,71,500	6,52,71,500
Other Equity	11	(5,30,27,604)	(5,13,58,215)
2 Non-Current Liabilities			
Financial Liabilities		-	-
Deferred tax liabilities(net)		-	-
3 Current liabilities			
Financial liabilities			
(a) Borrowings	12	3,31,302	17,56,302
(b) Trade Payable	13	1,07,318	1,11,779
(c) Other financial liabilities	14	0	2,50,00,000
Other Current Liabilities	15	15,477	10,981
Provisions	16	17,700	90,747
Total		1,27,15,693	4,08,83,094
Summary of Significant Accounting Policies	2		
See other notes to Accounts			

Notes referred to above form part of Balance Sheet

As per our report of even date attached. For Laxmikant Kabra & Co. LLP

Chartered Accountants

Firm Registration No.: 117183W/W100736

For and on behalf of the Board

Sd- Sd- SdShirish Shetye (Director) Prakash shah (Director)

CA Laxmikant Kabra

Partner

Membership No.: 101839

UDIN: 22101839AMEBNZ9087Sd-Sd-Place: MumbaiVaishali VaghasiyaJayesh Ramchandra PatilDate: 30th May, 2022(Company Secretary)(Chief Finance Officer)

Statement of Profit and Loss for the year ended 31st March, 2022

(Amount in ₹)

			Amount in V)
Particulars	Note No.	As at 31.03.2022	As at 31.03.2021
I. Revenue from operations		0	0
II. Other Income	17	5,75,680	7,39,261
Total Revenue(I+II)		5,75,680	7,39,261
III. Expenses			
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade			
		0	0
Employee benefit expense	18	5,99,972	5,22,286
Depreciation and amortization expenses	3	37,174	49,310
Other expenses	19	3,85,38,775	25,64,335
Total Expenses		3,91,75,921	31,35,931
IV. Profit/(Loss) before exceptional items and tax		(3,86,00,241)	(23,96,670)
V. Exceptional Items		0	0
VI. Profit /(Loss) after exceptional item before tax (IV+V)		(3,86,00,241)	(23,96,670)
VII. Tax Expenses:			
Current Tax		0	0
MAT		0	0
Deferred Tax		2,180	4,349
VIII. Profit/(Loss) for the year after tax (VI-VII)		(3,85,98,061)	(23,92,321)
IX. Other Comprehensive Income			
(A) Items that will not be reclassified to profit or loss			
(i) Gain/(loss) recognized on fair valuation of financial assets		(25,762)	33,21,371
(ii) Income Tax relating to items that will not reclassified to profit or Loss		6,698	(8,81,886)
(B) Items that may be reclassified to profit or loss			
(i) Provision for change in value of investments		0	0
(ii) Income Tax relating to items that may be reclassified to profit or Loss		0	0
Reclassification of loss on Asset held for Sale		3,69,47,738	0
Total Other Comprehensive Income (A(i)+(ii))		3,69,28,673	24,39,485
X. Total Comprehensive Income for the period (VIII)+(IX)		(16,69,388)	47,164
XII. Earning per equity share of Rs. 10 each:			
(1) Basic and Diluted		(6.55)	(0.41)

Notes referred to above form part of Profit & Loss

As per our report of even date attached. For Laxmikant Kabra & Co. LLP

Chartered Accountants

Firm Registration No.: 117183W/W100736

For and on behalf of the Board

Sd- Sd- SdShirish Shetye (Director) (Director)

CA Laxmikant Kabra

Partner

Membership No.: 101839

UDIN: 22101839AMEBNZ9087Sd-Sd-Place: MumbaiVaishali VaghasiyaJayesh Ramchandra PatilDate: 30th May, 2022(Company Secretary)(Chief Finance Officer)

CASH FLOW STATEMENT FOR THE YEAR ENDED 31 ST MARCH, 2022

Particulars	Year ended	Year ended
	31.03.2022	31.03.2021
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	(3,86,00,240.64)	(23,96,670.45)
Adjustments for		
Depreciation	37,174.00	49,310.20
Interest & Dividend Income	(5,75,680.00)	(14,17,918.00)
Operating profit before working capital changes	(3,91,38,746.64)	(37,65,278.25)
Working capital adjustments :-		
Increase / (Decrease) in Trade and Other Payables	(4,402.00)	(2,42,572.61)
Increase / (Decrease) in Borrowings	(14,24,698.00)	68,066.00
Increase / (Decrease) in Provisions	(73,047.00)	(32,000.00)
Increase / (Decrease) in Other Financial Liabilities	0.00	0.00
Increase / (Decrease) in Other Current Liabilities	4,496.00	(8,366.00)
(Increase) / Decrease in Trade Receivable	0.00	0.00
(Increase) / Decrease in Other Current Assets	5,46,944.64	(129.64)
Cash generated from / (used in) operations	(4,00,89,453.00)	(39,80,280.50)
Direct taxes paid (Net of Refunds)	-	-
Net cash (used in) / from generated from operating activities	(4,00,89,453.00)	(39,80,280.50)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant & Equipment	0.00	0.00
Proceeds Purchase/ Sale of investments	3,75,46,166.74	38,59,966.31
Interest & Dividend Income	5,75,680.00	14,17,918.00
Net cash (used in) / generated from investing activities	3,81,21,846.74	52,77,884.31
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease)of Unsecured Loan	32,74,674.00	(7,33,088.00)
Net cash (used in) / generated from financing activities	32,74,674.00	(7,33,088.00)
- D. Net Increase/ decrease in cash and cash equivalents (A+B+C)	13,07,067.74	5,64,515.81
Cash and cash equivalents at the beginning of the year	9,90,360.75	4,25,844.91
Cash and cash equivalents at the end of the year	22,97,428.49	9,90,360.72

Notes referred to above form part of Profit & Loss

As per our report of even date attached. For Laxmikant Kabra & Co. LLP

Chartered Accountants

Firm Registration No.: 117183W/W100736

For and on behalf of the Board

Sd-Sd-**Shirish Shetye** Prakash shah (Director) (Director)

CA Laxmikant Kabra

Partner

Membership No.: 101839

UDIN: 22101839AMEBNZ9087

Sd-Sd-Place: Mumbai Vaishali Vaghasiya Jayesh Ramchandra Patil Date: 30th May, 2022 (Company Secretary) (Chief Finance Officer)

NOTES FORMING PART OF THE BALANCE SHEET AS AT 31.3.2022

Notes to Financial Statements for the year ended 31st March, 2022

1. Corporate Information

Bacil Pharma Limited ("the Company") is a public limited company incorporated under the provisions of the Companies Act, 1956 and listed on the Bombay Stock Exchange. The Registered office is situated at 71, Laxmi Building, 4th Floor, Sir P. M. Road, Fort, Mumbai -400 001. The main object of the Company is to undertake Pharmaceutical business.

The financial statements were authorized for issue in accordance with the Board resolution passed on 30th May, 2022.

2. Significant Accounting Policies

2.1 Compliance with IND-AS

The Company has prepared financial statements for the year ended March 31, 2022 in accordance with Indian Accounting Standards (Ind AS) notified by the Ministry of Corporate affairs under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) together with the comparative period data as at and for the year ended March 31, 2021.

2.2 Basis of preparation and presentation

The financial statements prepared on the historical cost basis, except for certain financial assets that are measured at fair values at the end of each reporting period as explained in the accounting policies below.

The financial statements are prepared in INR and all values are rounded to the nearest Lakhs, except when otherwise stated. The company has consistently applied the following accounting policies to all periods presented in these financial statements.

a) Current versus non-current classification of assets and liabilities:

The Company presents assets and liabilities in the Balance sheet based on current/non-current classification. An asset is treated as current when it is:

- Expected to be realized or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realized within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The Operating Cycle is the time between the acquisition of assets for business purposes and their realization into cash and cash equivalents.

b) Property, Plant and Equipment:

Property, Plant and Equipment are recorded at their cost of acquisition, net of refundable taxes or levies, less accumulated depreciation and impairment losses, if any. The cost thereof comprises of its purchase price, including import duties and other non-refundable taxes or levies and any directly attributable cost for bringing the asset to its working condition for its intended use.

An item of property, plant and equipment and any significant part initially recognised is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the Statement of Profit or Loss when the asset is de-recognised.

Machinery Spares which can be used only in connection with a particular item of Fixed Asset and the use of which is irregular, are capitalized at cost. The cost thereof comprises of its purchase price, including import duties and other non-refundable taxes or levies and any directly attributable cost for bringing the asset to its working condition for its intended use.

For transition to Ind AS, the Company has elected to continue with the carrying value of all its property, plant and equipment and other Non-current Assets recognised as on 1st April, 2016 (date of transition) measured as per previous GAAP as its deemed cost on the date of transition.

Depreciation:

Depreciation on Property, Plant and Equipment and Investment Properties is provided on different class of assets based on the method and on the basis of its useful lives as per Schedule II of the Companies Act, 2013, Depreciation on Fixed Assets other than Plant and Machinery is provided on Written down value Method.

Depreciation on additions to Fixed Assets is provided on pro-rata basis from the date of acquisition or installation.

Impairment of Property Plant and Equipment & other Non-Current Assets:

Carrying amount of tangible and intangible assets are reviewed at each Balance Sheet date. These are treated as impaired when the carrying cost thereof exceeds its recoverable value. Recoverable value is higher of the asset's net selling price or value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Net selling price is the amount receivable from the sale of an asset in an arm's length transaction between knowledgeable, willing parties, less the cost of disposal. An impairment loss is charged for when an asset is identified as impaired.

c) Fair Value Measurement:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

d) Financial instruments:

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

FINANCIAL ASSETS

Initial recognition and measurement-

All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date.

Subsequent measurement-

For purposes of subsequent measurement, financial assets are classified in three categories:

- i) Financial assets measured at fair value through other comprehensive income (FVTOCI)
- ii) Financial assets measured at fair value through profit or loss (FVTPL)
- iii) Financial assets at amortized cost

Equity instruments

All equity instruments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading are classified as at FVTPL. For all other equity instruments, an irrevocable choice is made on initial recognition to measure it at FVTOCI. All fair value changes on such investments, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to profit or loss, even on sale or disposal of the investment. However, on sale or disposal the company may transfer the cumulative gain or loss within equity.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e. removed from the Company's balance sheet) when:

• The contractual rights to receive cash flows from the asset have expired, or The Company has transferred its rights to receive contractual cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

On Derecognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognized in OCI and accumulated in equity is recognized in profit or loss if such gain or loss would have otherwise been recognized in profit or loss on disposal of that financial asset.

FINANCIAL LIABILITIES:

Initial Recognition and Measurement:

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts.

Subsequent Measurement:

This is dependent upon the classification thereof as under:

Loans and Borrowings:

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the statement of profit and loss.

Derecognition:

A financial liability is de-recognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

Equity Instruments:

An equity instrument is any contract that evidences a residual interest in the assets of an entity in accordance with the substance of the contractual arrangements. These are recognised at the amount of the proceeds received, net of direct issue costs.

e) Revenue Recognition:

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the amount is received. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government, discounts and rebates.

Other Operating Revenue:

Revenue in respect of other income is recognized only when it is reasonably certain that ultimate collection will be made.

Interest Income:

Interest Income from Financial Assets is recognized using the Effective Interest Rate (EIR) on amortized cost basis.

Dividend Income:

Dividend income is recognized when the Company's right to receive the payment is established, which is generally when shareholders approve the dividend.

f) Employee Benefits:

Short term employee benefits are those which are payable wholly within twelve months of rendering service and are recognized as an expense at the undiscounted amount in Statement of Profit and Loss of the year in which the related service is rendered.

g) Borrowing Costs:

Borrowing costs comprising of interest and other costs that are incurred in connection with the borrowing of funds that are attributable to the acquisition or construction of qualifying assets are considered as a part of cost of such assets less interest earned on the temporary investment. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to Statement of profit and loss in the year in which they are incurred.

h) Taxes on Income:

Current Income Taxes:

Current income tax liabilities are measured at the amount expected to be paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognized directly in other comprehensive income / equity is recognized similarly and not in the statement of profit and loss. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred Taxes:

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred tax liabilities are recognized for all taxable temporary differences, when the deferred tax liability arises from an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.

Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized, except, when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognized outside profit or loss is recognized outside profit or loss. Deferred tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities.

MAT:

Minimum Alternate Tax (MAT) paid in accordance with the tax laws in India, which give rise to future economic benefits in the form of adjustment of future income tax liability, is considered as an asset if there is convincing evidence that the Company will pay normal income tax after the specified years. Accordingly, MAT is recognized as deferred tax asset in the Balance Sheet when the asset can be measured reliably and it is probable that the future economic benefits associated with it will flow to the Company.

i) Provisions, Contingent Liabilities and Contingent Assets:

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources.

When the Company expects part or entire provision to be reimbursed, the same is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

A Contingent Liability is a possible obligation that arises from past events and the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of enterprise or a present obligation that arises from past events that may, but probably will not, require an outflow of resources.

Both provisions and contingent liabilities are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. Contingent Liabilities are not recognized but are disclosed in the notes. Contingent assets are neither recognized nor disclosed in the Financial Statements.

j) Earnings Per Share:

Basic Earnings Per Share is calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. The weighted average numbers of equity shares outstanding during the year are adjusted for events including a bonus issue, bonus element in right issue to existing shareholders, share split, and reverse share split (consolidation of shares).

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of equity shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

k) Cash and Cash Equivalent:

Cash and cash equivalent for the purpose of Cash Flow Statement comprise cash at bank and in hand.

1) Statement of Cash Flow:

Cash flows are reported using the indirect method, whereby profit / (loss) before tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

m) Segment Reporting:

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The Board of Directors of the Company has been identified as being the Chief Operating Decision Maker (CODM) by the management of the Company. The Company has single reportable segments. However the Company has no separate reportable segment.

n) Significant Accounting Judgements, Estimates and Assumptions:

The preparation of Financial Statements is in conformity with the recognition and measurement principles of Ind AS which requires the management to make judgements for estimates and assumptions that affect the amounts of assets, liabilities and the disclosure of contingent liabilities on the reporting date and the amounts of revenues and expenses during the reporting period and the disclosure of contingent liabilities. Differences between actual results and estimates are recognized in the period in which the results are known/materialize.

i) Estimation of current tax expense and deferred tax:

The calculation of the Company's tax charge necessarily involves a degree of estimation and judgment in respect of certain items whose tax treatment cannot be finally determined until resolution has been reached with the relevant tax authority or, as appropriate, through a formal legal process. The final resolution of some of these items may give rise to material profits/losses and/or cash flows. Significant judgments are involved in determining the provision for income taxes, including amount expected to be paid/recovered for uncertain tax positions.

ii) Recognition of deferred tax assets/ liabilities:

The recognition of deferred tax assets/liabilities is based upon whether it is more likely than not that sufficient and suitable profits will be available in the future against which the reversal of temporary differences can be deducted. To determine the future taxable profits, reference is made to the latest available profit forecasts.

iii) Estimated fair value of Financial Instruments:

The fair value of financial instruments that are not traded in an active market is determined using valuation techniques. The Management uses its judgment to select a variety of methods and make assumptions that are mainly based on market conditions existing at the end of each reporting period.

Note 3: Property Plant and Equipments:

Particulars	Gre	oss Block			Depreciation		on		
	Opening as on 01.04.2021	Additi ons during the year	Deduction/ diminution in value during the year**	Closing As at 31.03.2022	Opening as on 01.04.20 21	durin g the year	Closing as at 31.03. 2022	WDV as on 31st March 2022	WDV as on 31st March 2021
Held for Sale									
Land & Building- Unit I	2,07,68,787	-	-	-	-	-	-	-	2,07,68,787
Leasehold Land- Unit II	8,21,477	-	-	-	-	-	-	-	8,21,477
Plant & Machinery	3,34,73,019	-	-	-	-	-	-	-	3,34,73,019
Other Non-current Assets*	68,84,455	-	-	-				-	68,84,455
Total	6,19,47,738	-	-	-	-	-	-	-	2,50,00,000
Previous Year	6,19,47,738	-	3,69,47,738	2,50,00,000	-	-	-	2,50,00,000	2,50,00,000
Other Fixed Assets									
Office Equipment	65,070	-	-	65,070	44,659	5,915	50,574	14,496	20,411
Furniture and Fixture	3,81,028	-	-	3,81,028	2,68,814	29,052	2,97,867	83,161	1,12,214
Computer & Printers	1,42,670	-	-	1,42,670	1,28,911	2,207	1,31,118	11,552	13,759
Total	5,88,768		-	5,88,768	4,42,384	37,174	4,79,559	1,09,209	1,46,384
Previous Year	5,88,768	-	-	5,88,768	3,93,074	49,310	4,42,384	1,46,384	

^{*}Represents preliminary expenses pending allocation capitalized.

The Company has entered into an agreement for sale of its Land and Building, Leasehold Land and Plant & Machinery on "as is where is basis" for a lump sum consideration of Rs. 250 Lakhs based on which the Fair value of all the assets held for sale has been taken as Rs. 250 Lakhs and the difference between cost of assets held for sale and the fair value of the assets has been shown diminution in value of all assets held for sale as the measurement of diminution in value for each asset was not possible.

Note 4: Non-Current Investments

Particulars	As at 31.03.2022	As at 31.03.2021
Investment measured at Fair Value through Other Comprehensive Income Investments in Equity Instruments 65,700 Equity Shares, Mayur Flooring Limited 2,10,000 Equity Shares Khemsum Apparels Overseas Limited	2,56,230 21,00,000	2,56,230 21,00,000
TOTAL	23,56,230	23,56,230

Note 5: Non Current Assets - Loans

Particulars	As at	As at
	31.03.2022	31.03.2021
Unsecured Considered Good		
Loan to Others	60,08,633	92,83,307
TOTAL	60,08,633	92,83,307

Note 6: Deferred Tax Assets (Net)

Particulars	As at	As at
	31.03.2022	31.03.2021
Opening Deferred Tax	10,75,462	19,52,999
Liability/(Asset) occurred on change in value of investments	8,878	(8,77,537)
Liability/(Asset) occurred due to Fixed Assets Depreciation	-	-
TOTAL	10,84,340	10,75,462

^{**}Diminution in value occurred on the fair value recognition of assets held for sale in accordance with Ind AS 105.

Note 7: Current Investments

Particulars	As at 31.03.2022	As at 31.03.2021
Investment measured at Fair Value through Profit & Loss Investments in Equity Instruments (Quoted)	48,00,795	53,99,134
Add: Provision for change in value of Investment	(40,36,590)	(40,10,827)
TOTAL	7,64,205	13,88,307

Note 8: Cash & Cash Equivalents

Particulars	As at	As at
	31.03.2022	31.03.2021
Balance with Bank (Current Account)	18,55,496	1,32 718
Cash in Hand	4,41,870	8,57,643
TOTAL	22,97,366	9,90,361

Note 9: Other Current Assets

Particulars	As at	As at
	31.03.2022	31.03.2021
Staff Advance	0	5,12,000
MSEB Deposit	60,620	60,620
TDS Receivable	35,179	70,294
Other Receivable	0	130
TOTAL	95,799	6,43,044

Note 10: Equity Share Capital

Particulars	As at	As at
	31.03.2022	31.03.2021
Authorized Capital 80,00,000 (Previous Year 80,00,000) Equity Shares of Rs. 10/- each	8,00,00,000	8,00,00,000
TOTAL	8,00,00,000	8,00,00,000
Issued, Subscribed and Paid up Capital 58,90,000 (Previous Year 58,90,000) Equity Shares of Rs. 10/- each, Fully paid up Add: Share Forfeited	5,89,00,000 63,71,500	5,89,00,000 63,71,500
TOTAL	6,52,71,500	6,52,71,500

Reconciliation of No. of Shares outstanding at the beginning and at the end of the Year

Particulars	As at	As at
	31.03.2022	31.03.2021
Number of Equity Shares at the beginning	58,90,000	58,90,000
Number of Equity Shares at the end	58,90,000	58,90,000

Details of the Shareholders holding more than 5% of Equity Shares in the Company

Particulars	No of Shares Held	% of Shares
Prakash Bhoorchand Shah		
Current Year	10,74,430	18.24%
Previous Year	10,74,430	18.24%
Gulechha Investment and Trading Company Private Limited		
Current Year	3,73,000	6.33%
Previous Year	3,73,000	6.33%
Rapport Investment and Trading Company Private Limited		
Current Year	9,17,300	15.57%
Previous Year	9,17,300	15.57%

Note 11: Other Equity

Particulars	As at	As at
	31.03.2022	31.03.2021
Surplus (Profit and Loss Account)		
Opening Balances	(5,13,58,215)	(5,14,05,379)
Add/Less: Provision for change in value of investments	40,36,590	33,21,372
Add/Less: Tax adjustment	3,28,92,082	(8,81,886)
Add/Less: Profit/(Loss) of the year	(3,85,98,061)	(23,92,322)
Balance as at end of the year		
TOTAL	(5,30,27,604)	(5,13,58,215)

Note 12: Current Borrowings

Particulars	As at	As at
	31.03.2022	31.03.2021
Borrowings from Director	3,31,302	17,56,302
TOTAL	3,31,302	17,56,302

Note 13: Current Liabilities- Trade Payables

Particulars	As at	As at
	31.03.2022	31.03.2021
Total outstanding dues of Micro Enterprises and Small Enterprises	0	0
Total outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	1,07,318	1,11,779
TOTAL	1,07,318	1,11,779

Note 14: Current Liabilities- Other Financial Liability

Particulars	As at	As at
	31.03.2022	31.03.2021
Advance received against assets held for sale	0	2,50,00,000
TOTAL	0	2,50,00,000

Note 15: Other Current Liabilities

Particulars	As at 31.03.2022	As at 31.03.2021
TDS on Professional Fees	15,477	10,981
Audit Fees Payable	0	0
TOTAL	15,477	10,981

Note 16: Current Liabilities- Provisions

Particulars	As at	
	31.03.2022	31.03.2021
Provision for Audit Fees	0	50,000
Provision for Employee Benefit Expenses	0	0
Provision for Professional Tax	0	0
Provision for Expenses	17,700	40,747
TOTAL	17,700	90,747

Note 17: Other Income

Particulars	As at 31.03.2022	As at 31.03.2021
Dividend	135	6,173
Interest	5,75,545	7,33,088
TOTAL	5,75,680	7,39,261

Note 18: Employee Benefit Expenses

Particulars	As at	As at
	31.03.2022	31.03.2021
Salary & Wages	5,77,000	4,90,700
Staff Welfare Expenses	22,972	31,586
TOTAL	5,99,972	5,22,286

Note 19: Other Expenses

Particulars	As at	As at
	31.03.2022	31.03.2021
Amount written off	0	2,97,209
Annual Custody Fees	26,550	26,550
Audit Fees	59,000	59,000
Auditor's Remuneration - Certification	0	0
Bank Charges	374	1,074
Books & Periodicals	7,987	6,600
Conveyance	32,102	24,000
Demat Charges	590	1,040
Electricity Charges	19,432	4,772
Factory Expenses	0	0
Filing Fees - R.O.C.	5,400	23,900
Insurance Charges	0	0
Interest on Delay Payment	8,168	45,604
Interest on TDS	0	0
Listing Fees	4,56,660	3,54,000
Miscellaneous Expenses	22,115	13,562
NSDL Fees	11,125	28,660
Office Expenses	28,620	16,716
Postage & Telegram	872	80
Printing & Stationery	16,064	14,864
Professional Fees	80,400	65,000
Professional Tax - Company	0	2,500
Professional Tax - Employees	0	0
Publication Charges	21,795	27,676
Rates & Taxes	9,000	0
R & T Exp	54,600	86,056
Repairs & Maintenance	0	0
Secretarial Audit Fees	0	0
Telephone Charges	17,275	8,169
Travelling Expenses	33,917	14,470
Vehicle Expenses	33,932	0
Profit/(Loss) on sale of Investments	6,33,259	14,24,011
Website Expenses	11,800	18,822
Loss on Asset held for Sale	3,69,47,738	0
TOTAL	3,85,38,775	25,64,335

Note 20: Other Notes to Accounts

I. Related Party Information & Transactions with Related Parties:

The Company has not entered into any related party transactions during the financial year 2021-2022.

II. Segment Reporting:

The Company has no separate reporting segment.

III. Financial Instrument:

The significant accounting policies, including the criteria of recognition, the basis of measurement and the basis on which income and expenses are recognized, in respect of each class of financial asset, financial liability, and equity instrument are disclosed in note 2.2 of the IndAS Financial Statement.

(a) Financial Assets and Liabilities

The carrying values of financial instruments by categories as at 31st March, 2022 are as follows:

Particulars	Note No.	Fair Value through Profit / Loss	Fair Value Through OCI	Amortized Cost	Total carrying Value
Financial Assets					
Non-current					
Investment	4	23,56,230	-	-	23,56,230
Loans & Advances	5	-	-	60,08,633	60,08,633
Current					
Investment	7	-	7,64,205	-	7,64,205
Trade receivables	8	-	-	-	-
Cash and cash equivalents	9	-	-	22,97,366	22,97,366
TOTAL		23,56,230	7,64,205	83,05,999	1,14,26,434
Financial Liabilities					
<u>Current</u>					
Trade Payables	13	-	-	1,07,318	1,07,318
Other Financial liabilities	14	-	-	0	0
Other Current Liabilities	15	-	-	15,477	15,477
TOTAL		-	-	1,22,795	1,22,795

The carrying values of financial instruments by categories as at 31st March, 2021 are as follows:

Particulars	Note No.	Fair Value through Profit / Loss	Fair Value Through OCI	Amortized Cost	Total carrying Value
Financial Assets					
Non-current					
Investment	4	23,56,230	-	-	23,56,230
Loans & Advances	5	-	-	92,83,307	92,83,307
Current					
Investment	7	-	13,88,307	-	13,88,307
Trade receivables	8	-	-	-	-
Cash and cash equivalents	9	-	-	9,90,361	9,90,361
TOTAL		23,56,230	13,88,307	1,02,73,668	1,40,18,205
Financial Liabilities					
Current					
Trade Payables	13	-	-	1,11,779	1,11,779
Other Financial liabilities	14	-	-	2,50,00,000	2,50,00,000
Other Current Liabilities	15			11,283	11,283
TOTAL		-	-	2,51,23,062	2,51,23,062

Fair Value Hierarchy

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consist of the following three levels:

- Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets and liabilities.
- Level 2: Inputs are other than quoted prices included within level 1 that are observable for the asset or liability either directly (i.e. prices) or indirectly (i.e. derived from prices).
- Level 3: Inputs are not based on observable market data unobservable inputs. Fair value are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

The following table summarizes financial assets and liabilities measured at fair value on a recurring basis and financial assets that are not measured on fair value on recurring basis (but fair value disclosures are required)

As at 31st March, 2021	Level 1	Level 2	Level 3	Total
Financial Assets :				
Investments measured at Fair value through Other				
Comprehensive Income				
Investments in Quoted Equity Shares	7,64,205	-	-	7,64,205
Investments measured at Fair value through Profit &				
Loss				
Investments in Quoted Shares	7,64,205	-	-	7,64,205

As at 31st March, 2021	Level 1	Level 2	Level 3	Total
Financial Assets :				
Investments measured at Fair value through Other Comprehensive Income				
Investments in Quoted Equity Shares	13,88,307	-	-	13,88,307
Investments measured at Fair value through Profit &				
Loss Investments in Quoted Shares	13,88,307	-	-	13,88,307

Notes referred to above form part of Balance Sheet

As per our report of even date attac0hed. For Laxmikant Kabra & Co. LLP

Chartered Accountants

Firm Registration No.: 117183W/W100736

For and on behalf of the Board

Sd- Sd- SdShirish Shetye Prakash shah
(Director) (Director)

CA Laxmikant Kabra

Partner

Membership No.: 101839

UDIN: 22101839AMEBNZ9087 Sd- Sd-

Place: Mumbai Vaishali Vaghasiya Jayesh Ramchandra Patil
Date: 30th May, 2022 (Company Secretary) (Chief Finance Officer)

BACIL PHARMA LIMITED

CIN: L24200MH1987PLC043427 Registered Office: 71, Laxmi Building, Sir P. M. Road, Fort, Mumbai - 400001

BALLOT FORM

Pursuant to Clause 35(B) of the Listing Agreement

Nam	e and Registered address of the :			
Sole	/ First named Member			
Nam	te (s) of joint member (s), if any :			
Regi	stered Folio No. / DP ID / Client ID :			
No.	of Shares held :			
Notic 2022	e hereby exercise my / our vote (s) in respect of the Resolutions to e of the 35th Annual General Meeting of the Company to be held by sending my/our assent or dissent to the said resolution(s) by selow.	on Thursday, the	29th day of Sep	otember,
ITEM NO	Description of Resolution	Number of Equity Share held	I / We assent to the resolution	I / We dissent to the resolution
			(FOR)	(AGAINST)
	Ordinary Business		(FOR)	(AGAINST)
1.	Ordinary Business To receive, consider, and, adopt the Audited Financial Statements of the Company as at 31st March, 2022 and Reports of the Directors' and Auditors' thereon.		(FOR)	(AGAINST)
1.	To receive, consider, and, adopt the Audited Financial Statements of the Company as at 31st March, 2022 and Reports of the Directors' and		(FOR)	(AGAINST)
	To receive, consider, and, adopt the Audited Financial Statements of the Company as at 31st March, 2022 and Reports of the Directors' and Auditors' thereon. To re-appoint M/s. Laxmikant Kabra & Co. LLP, Chartered Accountants as statutory auditors of the Company and to fix their		(FOR)	(AGAINST)
	To receive, consider, and, adopt the Audited Financial Statements of the Company as at 31st March, 2022 and Reports of the Directors' and Auditors' thereon. To re-appoint M/s. Laxmikant Kabra & Co. LLP, Chartered Accountants as statutory auditors of the Company and to fix their remuneration:		(FOR)	(AGAINST)
2.	To receive, consider, and, adopt the Audited Financial Statements of the Company as at 31st March, 2022 and Reports of the Directors' and Auditors' thereon. To re-appoint M/s. Laxmikant Kabra & Co. LLP, Chartered Accountants as statutory auditors of the Company and to fix their remuneration: Special Business To appoint Mrs. Suman Shah (DIN: 01764668) as Non-Executive Non-		(FOR)	(AGAINST)
2.	To receive, consider, and, adopt the Audited Financial Statements of the Company as at 31st March, 2022 and Reports of the Directors' and Auditors' thereon. To re-appoint M/s. Laxmikant Kabra & Co. LLP, Chartered Accountants as statutory auditors of the Company and to fix their remuneration: Special Business To appoint Mrs. Suman Shah (DIN: 01764668) as Non-Executive Non-		(FOR)	(AGAINST)

INSTRUCTIONS

- i. Unsigned, incomplete or incorrectly ticked forms are liable to be rejected and the decision of the Scrutinizer on the validity of the forms will be final.
- ii. In the event member casts his votes through both the processes i.e. e-voting and ballot form, the votes in the electronic system would be considered and the ballot form would be ignored.
- iii. There will be only one ballot form for every Folio/DP ID Client ID irrespective of the number of joint member.
- iv. In case of joint holders, the ballot form should be signed by the first named shareholder and in his/her absence by the next named shareholders.
- v. Where the ballot form has been signed by an authorised representative of the Body corporate/Trust/Society, etc. a certified copy of the relevant authorization/Board resolution to vote should accompany the ballot form.
- vi. For the resolutions, explanatory statement and instructions for e-voting procedure please refer notice of the 30th annual general meeting of the Company.

BACIL PHARMA LIMITED

CIN: L24200MH1987PLC043427 Registered Office: 71, Laxmi Building, Sir P. M. Road, Fort, Mumbai - 400001

PROXY FORM

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies [Management and Administration) Rules, 2014]

	-		,	-	
Na	me of the member(s)	:			
Re	gistered address	:			
E-r	mail ID	:			
Fol	lio No./DP ID & Client ID	:			
l/We,	bearing the member(s) of		_ shares of Bacil Pharma Limited, I	nereby appoint:	
1.	1. Name :				
	Address:				
	E-mail address:			or failing him	
2.	Name :				
	Address:				
	E-mail address:			or failing him	
3.	Name :				
	Address:				
	E-mail address:			or failing him	
				the 35th Annual General Meeting of the	
				1, Laxmi Building, Sir P. M. Road, Fort,	
	bai – 400 001 and at any adjournment	the	reof in respect of such resolutions a	as are indicated below:	
Or	dinary Business				
1.	To receive, consider, and, adopt the the Directors' and Auditors' thereon.	Audi	ted Financial Statements of the Con	npany as at 31st March, 2022 and Reports of	
2.	To re-appoint M/s. Laxmikant Kabra their remuneration:	& (Co. LLP, Chartered Accountants as s	tatutory auditors of the Company and to fix	
Sp	ecial Business				
3.	To appoint Mrs. Suman Shah (DIN: 0	1764	4668) as Non-Executive Non-Indepe	ndent Director of the Company.	
Signe	ed this day of	_ 20	022	Affix	
				Revenu e Stamp	
				of Re. 1	
Signa	ature of Shareholder		Signature of Proxy		

- Notes:
 - 1. This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting.
 - 2. For the resolutions, explanatory statement and notes please refer notice of 30th Annual General Meeting.

BOOK - POST

If undelivered, please return to: **BACIL PHARMA LIMITED**71, Laxmi Building, Sir P. M. Road,
Fort, Mumbai – 400 001.